Sabon bincike: COVID-19 mai haɓaka rigakafin rigakafin 90% yana tasiri akan Omicron

Sabbin karatu: COVID-19 mai haɓaka rigakafin rigakafin 90% yana tasiri akan Omicron
Sabbin karatu: COVID-19 mai haɓaka rigakafin rigakafin 90% yana tasiri akan Omicron

Sabbin karatu uku na Amurka Cibiyoyin Kula da Cututtuka da Cututtuka (CDC)) ya bayyana cewa Pfizer-BioNTech da Moderna masu kara kuzari sun yi tasiri kashi 90% wajen hana mutane zuwa asibiti bayan sun kamu da cutar Omicron na COVID-19.

Abubuwan haɓakawa sun tabbatar da tasiri sosai a hanawa omicron-da alaka da asibiti, a cewar CDC.

Booster jabs kuma sun kasance masu tasiri 82% wajen hana sashen gaggawa da ziyartar kulawar gaggawa, bayanan bincike sun nuna.

Binciken ya ƙunshi manyan binciken farko na Amurka don duba rigakafin rigakafi omicron, in ji jami'an kiwon lafiya.

"Ya kamata Amurkawa su sami masu ƙarfafawa idan aƙalla watanni biyar suka shuɗe tun da suka kammala shirin su na Pfizer ko Moderna, amma miliyoyin da suka cancanci ba su samu ba," CDC's Emma Accorsi, daya daga cikin marubutan binciken ya ce.

Takardun sun yi nuni da binciken da ya gabata - ciki har da nazarce-nazarce a Jamus, Afirka ta Kudu da Burtaniya - wanda ke nuni da cewa alluran rigakafin da ake da su ba su da tasiri a kan Omicron fiye da nau'ikan cutar sankara na farko, amma kuma masu haɓakar allurai suna haɓaka ƙwayoyin rigakafin ƙwayoyin cuta don haɓaka damar gujewa. bayyanar cututtuka.

Print Friendly, PDF & Email

Shafin Farko